Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.
IPO Year: 2018
Exchange: NASDAQ
Website: gritstonebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 2/28/2024 | $4.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | Outperform | Evercore ISI | |
| 3/28/2023 | $8.00 | Buy | B. Riley Securities |
| 10/31/2022 | $6.00 | Overweight | Piper Sandler |
| 8/22/2022 | $2.00 | Neutral → Sell | Goldman |
| 12/15/2021 | $15.00 | Neutral | Goldman |
| 10/15/2021 | $20.00 | Buy | BTIG Research |
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo
-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ
EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from "off-the-shelf" vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 -- -- Clinical evidence building for differentiation of self-amplifying mRNA (samRNA) as a potential next-gen mRNA platform in infectious disease -- -- Cash, cash equivalents, marketable securities, and restricted cash of $185.2 million as of December 31, 2022 -- -- Gritstone to host conference call today at 4:30pm
EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its fourth quarter and full year 2022 financial results and provide a corporate update following market close on Thursday, March 9, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by webcast, visit: https://ir.gritstonebio.com/investors/eventsTo access by phone, dial: 1-877-407-4018Conference ID: 13734754 While not required, it is recommended you join five minutes prior to the event's start. An archived
-- Clinical programs continue to progress, with initial data from Phase 2 study of "off the shelf" SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA (samRNA) -- -- New credit facility provides financial flexibility entering period of multiple potential milestones -- -- Cash, cash equivalents, marketable securities and restricted cash of $159.2 million as of June 30, 2022 -- -- Gritstone will host a conference call today, August 4 at 4:30 p.m
EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results, and provide a corporate update. To access the conference call, dial 800-263-0877 five minutes prior to the start of the call and provide the event title: Gritstone bio Second Quarter 2022 Earnings Call, or the following passcode: 8108859. To access the webcast, visit https://event.webcasts.com/starthere.jsp?ei=1561514&tp_key=4f6eab0ea9 The archived webcast wi
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will report its financial results for the first quarter ended March 31, 2022 and provide recent clinical and corporate updates via a press release on Thursday, May 5, 2022 at 4:05pm Eastern Time (ET). To facilitate engagement with the company's shareholder base and connections with its investors, Gritstone is partnering with Say Technologies to enable shareholders to submit and upvote questions through Say's online portal, a selection of which will be answered
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
4 - Gritstone bio, Inc. (0001656634) (Issuer)
JMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform
JMP Securities initiated coverage of Gritstone bio with a rating of Mkt Outperform and set a new price target of $4.00
Evercore ISI initiated coverage of Gritstone bio with a rating of Outperform
B. Riley Securities initiated coverage of Gritstone bio with a rating of Buy and set a new price target of $8.00
Piper Sandler initiated coverage of Gritstone bio with a rating of Overweight and set a new price target of $6.00
Goldman downgraded Gritstone bio from Neutral to Sell and set a new price target of $2.00
Goldman resumed coverage of Gritstone bio with a rating of Neutral and set a new price target of $15.00
BTIG Research resumed coverage of Gritstone bio with a rating of Buy and set a new price target of $20.00
8-K - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
10-Q - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
DEFA14A - Gritstone bio, Inc. (0001656634) (Filer)
10-Q - Gritstone bio, Inc. (0001656634) (Filer)
8-K - Gritstone bio, Inc. (0001656634) (Filer)
Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, August 2 at 9:00 AM ET featuring J. Randolph Hecht, MD, (Professor, UCLA Gastrointestinal Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer (M
EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the Compensation Committee of the company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 39,000 shares of its common stock with an exercise price of $0.57, which is equal to the closing price of Gritstone's common stock on July 3, 2024, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options wil
EMERYVILLE, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the Compensation Committee of the company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 6,850 shares of its common stock with an exercise price of $0.75, which is equal to the closing price of Gritstone's common stock on June 7, 2024, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options wi
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will be participating in the following investor and scientific conferences: Goldman Sachs 45th Annual Global Healthcare Conference (Fireside Chat*)Date and Time: Tuesday, June 11, 2024 at 1:20pm ETLocation: Miami, FL JonesHealthcare Seaside Summit 2024 (1x1s)Dates: Monday, July 15 - Tuesday, July 16Location: Encinitas, CA 4th Annual mRNA-Based Therapeutics Summit (Panel)Panel Title: Unpacking 2024's Successes & Anticipating the Next Challenges to Advance the Future of mRNA-Base
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024 -- -- Nature Medicine publication of Phase 1 study of SLATE (off-the-shelf neoantigen vaccine) and AACR-presented improvements to EDGE™ (tumor antigen identification platform that was recently enhanced using large language models) highlight Gritstone's leadership in neoantigen-directed cancer vaccine field -- -- Latest data from Phase 1 CORAL-CEPI study highlights the durability and potential broa
-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo
-- IgG levels and neutralizing antibodies against variants of concern persisted for at least 12 months, consistent with previous findings -- -- Antigen-specific T cell responses increased in the majority of participants studied, including those living with HIV, after administration of any of the samRNA constructs -- -- Comprehensive data set demonstrates a consistent and strong immunogenicity profile across multiple patient populations in South Africa, including people living with HIV -- EMERYVILLE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented upda
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit
-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd
EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento
EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced the appointment of Lawrence "Larry" Corey, M.D., to its Board of Directors. An internationally renowned expert in virology, immunology and vaccine development, Dr. Corey is a former President and Director of Fred Hutchinson Cancer Center ("Fred Hutch"), a world-leading institution focused on prevention, diagnosis and treatment of cancer, HIV/AIDS and other diseases. Effective August 12, 2022, Dr. Corey replaces Richard Heyman, Ph.D. who stepped down as a Board Member after more than six years o
> Dr. Agarwal is Currently Chairwoman of Onxeo's Board, a Position Held Since June 2021 > Company Outlines Development Strategy Plans Including Preparation for U.S. Pre-IND Meeting for First-in-Class DDR Inhibitor AsiDNA® and Plans for Building Infrastructure in the United States > New Private Financing Expands Onxeo's Runway Into Second Quarter 2023 Regulatory News: Onxeo S.A. (PARIS:ALONX, Nasdaq First North Copenhagen: ONXEO))), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the appointment of Dr. Shefali Agarwal as President and Chief Executive O
EMERYVILLE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced the appointment of Celia Economides as executive vice president and chief financial officer. Separately, the company announced that Roman Yelensky, Ph.D., executive vice president and chief technology officer, will be stepping down to co-found and lead a new startup in the cancer diagnostics space, working alongside a major healthcare investor. Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone, remarked, "Celia brings a diverse and wel
During the last three months, 4 analysts shared their evaluations of Gritstone Bio (NASDAQ:GRTS), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 1 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.25, a high estimate of $5.00, and a low estimate of $3.00. This current average has decreased by 22.73% from the
JMP Securities analyst Roy Buchanan reiterates Gritstone Bio (NASDAQ:GRTS) with a Market Outperform and maintains $5 price target.
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
B. Riley Securities analyst Mayank Mamtani reiterates Gritstone Bio (NASDAQ:GRTS) with a Buy and lowers the price target from $6 to $3.
In the latest quarter, 4 analysts provided ratings for Gritstone Bio (NASDAQ:GRTS), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.0, with a high estimate of $7.00 and a low estimate of $4.00. A decline of 9.09% from the prior averag
HC Wainwright & Co. analyst Sean Lee maintains Gritstone Bio (NASDAQ:GRTS) with a Buy and lowers the price target from $7 to $4.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings. Natera posted GAAP loss of 56 cents per share, compared to market expectations for a loss of 71 cents per share. The company's quarterly sales came in at $367.700 million versus estimates of $316.306 million. Natera, shares jumped 15.3% to $110.25 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Novavax, Inc. (NASDAQ:NVAX) gained 165% to $11.84 in pre-market trading after the company reported first-quarter results. AEye, Inc. (NASDAQ:LIDR) gained 38.1% to $1.63 in pre-market trading after the company disclosed a par
Gainers Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million. Novavax (NASDAQ:NVAX) shares rose 119.23% to $9.8. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 51.18% to $5.76. The company's market cap stands at $94.4 million. As per the news, the Q1 earnings report came out yesterday. Natera (NASDAQ:NTRA) shares moved upwards by 20.31% to $114.96. The market value of their outstanding shares is at $14.0 billion. The company's, Q1 earnings came out yesterday. XTL Biopharmaceu